Effects of proton pump inhibitors on in-stent restenosis in patients receiving clopidogrel: a retrospective analysis.
- Author:
Zhan-lu LI
1
;
Bin-quan ZHOU
;
Jun-hui ZHU
;
Guo-sheng FU
Author Information
- Publication Type:Journal Article
- MeSH: Angioplasty, Balloon, Coronary; Coronary Restenosis; etiology; Drug Antagonism; Drug Therapy, Combination; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; therapeutic use; Proton Pump Inhibitors; therapeutic use; Retrospective Studies; Risk; Stents; Ticlopidine; analogs & derivatives; therapeutic use
- From: Journal of Zhejiang University. Medical sciences 2011;40(6):667-672
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo determine the effect of proton pump inhibitor (PPI) on in-stent restenosis (ISR) in patients receiving clopidogrel therapy.
METHODSTotal 439 patients underwent percutaneous coronary intervention (PCI) were enrolled in the study,including 250 post-PCI patients discharged on clopidogrel alone and 189 patients discharged on clopidogrel with PPI. The in-stent restenosis (ISR) ratio of the patients in these two groups were observed.
RESULTSDuring a mean follow-up period of (13 ± 5.9) months, the post-PCI patients discharged on concomitant clopidogrel-PPI therapy had higher risk of ISR than those discharged on clopidogrel alone (19.6% Compared with 8%, P<0.001).
CONCLUSIONConcomitant use of clopidogrel and PPI after hospital discharge would increase the risk of ISR for post-PCI patients.
